Cyclo Therapeutics Revenue vs. Price To Sales
| CYTH Stock | USD 0.64 0.08 11.11% |
Total Revenue | First Reported 2000-09-30 | Previous Quarter 123.1 K | Current Value 233.8 K | Quarterly Volatility 140.9 K |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.68 | 0.9085 |
|
|
For Cyclo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyclo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyclo Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyclo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyclo Therapeutics over time as well as its relative position and ranking within its peers.
Cyclo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cyclo Therapeutics Price To Sales vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cyclo Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyclo Therapeutics value to that of its competitors to determine the firm's financial worth. Cyclo Therapeutics is rated third in revenue category among its peers. It also is rated third in price to sales category among its peers . The ratio of Revenue to Price To Sales for Cyclo Therapeutics is about 58,850 . As of now, Cyclo Therapeutics' Total Revenue is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclo Therapeutics' earnings, one of the primary drivers of an investment's value.Cyclo Revenue vs. Competition
Cyclo Therapeutics is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 10.65 Million. Cyclo Therapeutics retains roughly 1.08 Million in revenue claiming about 10% of equities under Health Care industry.
Cyclo Price To Sales vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Cyclo Therapeutics |
| = | 1.08 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Cyclo Therapeutics |
| = | 18.29 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Cyclo Price To Sales Comparison
Cyclo Therapeutics is currently under evaluation in price to sales category among its peers.
Cyclo Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cyclo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyclo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cyclo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cyclo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -20.1 M | -19 M | |
| Income Before Tax | -20.1 M | -19.1 M | |
| Total Other Income Expense Net | -7.2 K | -7.6 K | |
| Net Loss | -20.1 M | -19.1 M | |
| Income Tax Expense | 4.00 | 3.80 | |
| Net Loss | -19.4 M | -18.4 M | |
| Net Loss | -13.9 M | -13.2 M | |
| Change To Netincome | 328.8 K | 316.3 K | |
| Net Loss | (1.23) | (1.29) | |
| Income Quality | 0.81 | 0.85 | |
| Net Income Per E B T | 1.14 | 1.51 |
Cyclo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cyclo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyclo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyclo Therapeutics' important profitability drivers and their relationship over time.
Use Cyclo Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Cyclo Therapeutics Pair Trading
Cyclo Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Cyclo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclo Therapeutics to buy it.
The correlation of Cyclo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cyclo Therapeutics position
In addition to having Cyclo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Asset Management Thematic Idea Now
Asset Management
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Asset Management theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Management Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
To fully project Cyclo Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cyclo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cyclo Therapeutics' income statement, its balance sheet, and the statement of cash flows.